VOLITIONRX LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8775 USD | +5.85% |
|
+12.60% | +22.38% |
| May. 13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 26 | VolitionRx Limited Announces Board Changes | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 3.63M | Sales 2025 * | 16.48M | Capitalization | 72.05M |
|---|---|---|---|---|---|
| Net income 2024 * | -36M | Net income 2025 * | -32M | EV / Sales 2024 * | 17.4 x |
| Net cash position 2024 * | 8.9M | Net Debt 2025 * | 18.4M | EV / Sales 2025 * | 5.49 x |
| P/E ratio 2024 * |
-2.16
x | P/E ratio 2025 * |
-2.72
x | Employees | 110 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on VolitionRx Limited
More recommendations
| 1 day | +5.85% | ||
| 1 week | +12.60% | ||
| Current month | -2.49% | ||
| 1 month | +28.10% | ||
| 3 months | -15.62% | ||
| 6 months | +5.25% | ||
| Current year | +22.38% |
1 week
0.72
0.90
1 month
0.571.02
Current year
0.571.23
1 year
0.551.81
3 years
0.554.14
5 years
0.556.84
10 years
0.559.28
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 11-10-05 |
Terig Hughes
DFI | Director of Finance/CFO | 54 | 21-01-31 |
Gaetan Michel
COO | Chief Operating Officer | 51 | 21-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 11-10-05 |
Martin Faulkes
CHM | Chairman | 80 | 11-10-05 |
Guy Innes
BRD | Director/Board Member | 67 | 11-10-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 0.8775 | +5.85% | 309,762 |
| 24-05-10 | 0.829 | +2.36% | 83,603 |
| 24-05-09 | 0.8099 | +10.04% | 166,177 |
| 24-05-08 | 0.736 | +2.22% | 174,260 |
| 24-05-07 | 0.72 | -7.61% | 304,804 |
Delayed Quote Nyse, May 13, 2024 at 04:10 pm EDT
More quotes
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
08:30am
- Q1 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8775
USD
Average target price
3.725
USD
Spread / Average Target
+324.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.38% | 72.05M | |
| -24.86% | 10.26B | |
| -11.28% | 2.94B | |
| -12.92% | 2.19B | |
| -18.21% | 1.72B | |
| +60.76% | 1.4B | |
| +24.83% | 780M | |
| -4.59% | 736M | |
| -22.45% | 560M | |
| -0.60% | 293M |
- Stock Market
- Equities
- VNRX Stock